

SUPPLEMENTAL MATERIAL

Schulz et al., <http://www.jem.org/cgi/content/full/jem.20111117/DC1>

mouse #	treatment	tumor	d0	d3	d7	d10	d13	d17
MIF+/+ErbB2_155	vehicle	T1	41	73	245	331	494	837
MIF+/+ErbB2_196	vehicle	T1	14	51	122	171	449	731
MIF+/+ErbB2_222	vehicle	T1	33	33	163	278	502	857
MIF+/+ErbB2_237	vehicle	T1	33	61	110	286	449	771
		T2	41	41	147	196	457	808
MIF+/+ErbB2_163	17AAG	T1	33	24	41	41	64	98
		T2	41	51	64	77	92	122
		T3	41	52	63	63	33	24
MIF+/+ErbB2_181	17AAG	T1	33	33	61	110	147	122
MIF+/+ErbB2_182	17AAG	T1	41	61	61	110	151	73
MIF+/+ErbB2_202	17AAG	T1	110	122	110	61	69	101
MIF+/+ErbB2_223	17AAG	T1	31	14	14	12	18	61
		T2	14	8	8	8	14	41

mouse #	treatment	tumor	d0	d3	d7	d10	d13	d17
MIF-/-ErbB2_173	vehicle	T1	24	51	77	200	286	531
		T2	33	51	64	110	171	306
		T3	nd	33	73	196	196	306
MIF-/-ErbB2_213	vehicle	T1	14	41	41	51	110	196
MIF-/-ErbB2_225	vehicle	T1	33	41	102	102	204	294
		T2	14	20	41	61	110	196
MIF-/-ErbB2_232	vehicle	T1	33	33	49	122	229	337
		T2	24	43	54	151	261	408
MIF-/-ErbB2_269	vehicle	T1	49	65	196	327	490	735
MIF-/-ErbB2_171	17AAG	T1	20	20	20	38	131	393
		T2	nd	nd	13	64	163	245
MIF-/-ErbB2_172	17AAG	T1	14	14	37	129	171	327
		T2	14	14	33	143	143	408
		T3	64	64	64	92	122	179
MIF-/-ErbB2_204	17AAG	T1	20	51	98	98	196	327
MIF-/-ErbB2_207	17AAG	T1	46	98	131	163	280	367
		T2	41	41	31	71	122	196
		T3	14	14	18	18	61	172
		T4	14	14	31	31	171	286
MIF-/-ErbB2_208	17AAG	T1	33	55	73	147	196	408
		T2	nd	14	24	33	114	245
MIF-/-ErbB2_215	17AAG	T1	14	14	110	184	245	355
MIF-/-ErbB2_216	17AAG	T1	14	14	14	51	92	178
		T2	nd	nd	14	51	71	196
MIF-/-ErbB2_252	17AAG	T1	4	51	86	61	147	327

Figure S1. Overview of small tumors measured in mice. Detailed listing of all small MIF^{+/+}ErbB2 and MIF^{-/-}ErbB2 tumors (numbers indicate volumes in mm³), as summarized in Fig. 7 (A and B, top). Mice with small, comparably sized palpable tumors were treated with 17AAG or vehicle (EPL diluent) for 5 d a week, for 3 wk. Tumor sizes were measured twice a week by caliper (on days [d] 0, 3, 7, 10, 13, and 17) and tumor volumes were calculated as ellipsoid ($V = abc \times 4/3\pi$). Individual mice are listed (mouse #). The number of tumors per mouse is shown in the tumors column (T1, T2, etc).

A

mouse #	treatment	d0	d3	d7	d10	d13	d17
MIF+/+ErbB2_320	vehicle	225	257	367	450	653	927
MIF+/+ErbB2_272	17AAG	302	245	276	220	220	245
MIF+/+ErbB2_280	17AAG	114	131	114	131	192	184
MIF+/+ErbB2_322	17AAG	225	273	257	286	345	339

mouse #	treatment	d0	d3	d7	d10	d13	d17
MIF-/-ErbB2_227	vehicle	207	220	290	352	449	620
MIF-/-ErbB2_234	17AAG	367	404	429	367	347	429
MIF-/-ErbB2_340	17AAG	245	306	329	429	489	584
MIF-/-ErbB2_324	17AAG	115	143	196	216	331	286

B

mouse #	treatment	d0	d3	d7	d10	d13	d17
MIF+/+ErbB2_320	vehicle	1.00	1.15	1.64	2.00	2.91	4.13
MIF+/+ErbB2_272	17AAG	1.00	0.81	0.91	0.73	0.73	0.81
MIF+/+ErbB2_280	17AAG	1.00	1.14	1.00	1.14	1.68	1.61
MIF+/+ErbB2_322	17AAG	1.00	1.22	1.15	1.27	1.54	1.53

mouse #	treatment	d0	d3	d7	d10	d13	d17
MIF-/-ErbB2_227	vehicle	1.00	1.07	1.40	1.70	2.17	3.00
MIF-/-ErbB2_234	17AAG	1.00	1.10	1.17	1.00	0.95	1.17
MIF-/-ErbB2_340	17AAG	1.00	1.25	1.34	1.75	2.00	2.38
MIF-/-ErbB2_324	17AAG	1.00	1.24	1.70	1.88	2.88	2.48

Figure S2. Overview of large tumors measured in mice. Detailed listing of all larger MIF^{+/+}ErbB2 and MIF^{-/-}ErbB2 tumors (numbers indicate volumes in millimeters cubed; A), as summarized in Fig. 7 (A and B, bottom). Mice with larger tumors were treated with 17AAG or vehicle (EPL diluent) for 5 d a week, for 3 wk. Tumor sizes were measured twice a week (days [d] 0, 3, 7, 10, 13, and 17) and tumor volumes were calculated as ellipsoid ($V = abc \times 4/3\pi$). The response rate of larger tumors was normalized to the respective starting tumor volume and calculated as relative change (B). Individual mice are listed (mouse #). The largest tumor per mouse was analyzed.